Axis Biotec Innovative Wound Dressing’s IP Issued in Germany

RIO DE JANEIRO--()--Some wounds can be difficult to heal and the patients affected by them can suffer from infections, pain and other complications. A Brazilian product capable of revolutionizing wound treatment has had its Intellectual Property (IP) rights approved in Germany. Manufactured by Silvestre Labs®, of Axis Biotec Group, Colzen® is a 3 in 1 biocompatible wound dressing, composed of calcium alginate, cerium nitrate and collagen type I.

Colzen® is indicated for the management of wounds including: to burns, leg ulcers, pressure ulcers, diabetic foot ulcers, grafting areas, traumatic and surgical wounds.

With its unique composition, Colzen® offers three benefits in one product. Collagen promotes granulation and wound epithelialization, alginate controls the exudate forming a gel that guaranties the ideal moisture for the wound bed, and cerium nitrate that controls bacteria.

“Colzen® also provides convenience of treatment to the patient, as it must be replaced only every 72 hours. In contact with the wound, Colzen® becomes a transparent protective gel, which reduces pain while controlling bacteria and promoting healing cell proliferation in a physiologically humid environment. Colzen® easily molds to the contours of the wound and it may be cut to adjust when necessary,” says Eduardo Cruz, CEO and founder of Silvestre Labs®.

Silvestre Labs® is one of the few pharmaceutical companies in Brazil to perform the translation of scientific research into products that have benefited and continue to benefit thousands of people. His research focuses on cosmetic and dermatological pharmaceuticals.

Axis Biotec is a holding that sponsors and manages research, development and innovative business in health and life sectors. With strong expertise in R&D, and also in sales and marketing, the companies of the group have proven efficient in translating research into innovative products and services.

Several of the companies under Axis Biotec Brasil umbrella are located in the Rio de Janeiro's Biotech Development Park.

Colzen®’s IP has also been issued in Spain, China, The United States, France, Hong Kong, Italy, Japan, Portugal and Switzerland.

For further information, please contact ec@axisbiotec.com.br

Contacts

Silvestre Labs®
Graziela Beltrami
maketing2@silvestrelabs.com.br
Marketing Manager

Release Summary

A Brazilian product capable of revolutionizing wound treatment has had its Intellectual Property (IP) rights approved in Germany.

Contacts

Silvestre Labs®
Graziela Beltrami
maketing2@silvestrelabs.com.br
Marketing Manager